Clinical, humanistic, and economic outcomes between drug-eluting stent (DES) and bare metal stent (BMS): 18-month follow-up study

References

• Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. New Engl J Med 2006;354:483-95
   PubMed Web of Science ®Google Scholar
• Lee MKY. Recent advances in Percutaneous Coronary Intervention (PCI). Hong Kong Med Diary 2008;13:6-9
   Google Scholar
• P-Y. Updates on Percutaneous Coronary Intervention. Hong Kong Med Diary 2007;12:24-7
   Google Scholar
• Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-86
   PubMed Web of Science ®Google Scholar
• Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-4
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent: The TAXUS-IV Trial. Circulation 2004;109:1942-7
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol 2006;47:1350-5
   PubMed Web of Science ®Google Scholar
• Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-13
   PubMed Web of Science ®Google Scholar
• Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9
   PubMed Web of Science ®Google Scholar
• Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J of Medicine 2006;119:1056-61
   PubMed Web of Science ®Google Scholar
• Hassan AKM, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31:1172-80
   PubMed Web of Science ®Google Scholar
• Hospital Authority Statistical Report 2009 – 2010. Hong Kong: Hospital Authority, 2010
   Google Scholar
• Lau CP. Hong Kong College of Cardiology Statement on coronary drug-eluting stents for PCI. The Hong Kong College of Cardiology, 2006
   Google Scholar
• Eisenstein EL, Wijins W, Fajadet J, et al. Long-term clinical and economic analysis of the endeavor drug-eluting stent versus the driver bare-metal stent: 4-year results from the ENDEAVOR II Trial (Randomized controlled trial to evaluate the safety and efficacy of the medtronic AVE ABT-578 eluting driver coronary stent in de novo native coronary artery lesions). J Am Coll Cardiol Intv 2009;2:1178-87
   Web of Science ®Google Scholar
• Zhao F-h, Lü S-z, Li H, et al. Clinical outcomes and cost-utility after sirolimus-eluting versus bare metal stent implantation. Chin Med J 2010;123:2797-802
   PubMed Web of Science ®Google Scholar
• Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-33
   PubMed Web of Science ®Google Scholar
• Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-29
   PubMed Web of Science ®Google Scholar
• Neyt M, Brabandt HV, Devriese S, et al. Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy 2009;91:107-20
   PubMed Web of Science ®Google Scholar
• Bischof M, Briel M, Bucher HC, et al. Cost-effectiveness of drug-eluting stents in a US Medicare setting: a cost-utility analysis with 3-year clinical follow-up data. Value Health 2009;1:649-56
   Web of Science ®Google Scholar
• Filion KB, Roy AM, Baboushkin T, et al. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol 2009;103:338-44
   PubMed Web of Science ®Google Scholar
• Schafer PE, Sacrinty MT, Cohen DJ, et al. Cost-Effectiveness of Drug-Eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes 2011;4:408-15
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51
   PubMed Web of Science ®Google Scholar
• Dyer MTD, Goldsmith KA, Sharples LS, et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010;8:13
   PubMed Web of Science ®Google Scholar
• Spiraki C, Kaitelidou D, Papakonstantinou V, et al. Health-related quality of life measurement in patients admitted with coronary heart disease and heart failure to a cardiology department of a secondary urban hospital in Greece. Hellenic J Cardiol 2008;49:241-7
   PubMed Web of Science ®Google Scholar
• Ellis JJ, Eagle KA, Kline-Rogers EM, et al. Validation of the EQ-5D in patients with a history of acute coronary syndrome. Presented at the International Society for Pharmacoeconomics and Outcomes Research meeting, 17–19 May 2004, Washington DC
   Google Scholar
• Rabin R, Oemar M, Oppe M. EQ-5D-3L User guide: basic information on how to use the EQ-5D-3L instrument. Version 4.0. EuroQol Group, 2011
   Google Scholar
• Williams A. The measurement and valuation of health: a chronicle. Centre for Health Economics, York Health Economics Consortium, NHS Centre for Reviews & Dissemination, 1995
   Google Scholar
• World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Cost-effectiveness thresholds. http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed February 9, 2011
   Google Scholar
• Ong ATL, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Eur Heart J 2006;27:2996-3003
   PubMed Web of Science ®Google Scholar
• Hung CS, Cheng CL, Chao CL, et al. Cost-effectiveness of drug-eluting stents in patients with stable coronary artery disease. J Formos Med Assos 2011;110:109-14
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL Trial. J Am Coll Cardiol 2007;50:1299-302
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR, et al. Five-Year follow-up after sirolimus-eluting stent implantation: results of the SIRIUS (Sirolimus-eluting stent in de-novo native coronary lesions) Trial. J Am Coll Cardiol 2009;53:1488-97
   PubMed Web of Science ®Google Scholar
• Hirsch A, Verouden NJ, Koch KT, et al. Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris. Am J Cardiol 2009;104:333-7
   PubMed Web of Science ®Google Scholar